Related Experiment Videos
Improved prognosis for acquired aplastic anaemia
L A Pitcher1, I M Hann, J P Evans
1Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London, UK.
Insights
Outcomes for pediatric aplastic anemia have significantly improved. Modern treatments, including cyclosporine A, led to an 8-year survival rate of 84% in the recent cohort compared to 45% in the earlier group.
Area of Science:
- Pediatric Hematology
- Oncology
- Immunosuppressive Therapy
Background:
- Aplastic anemia is a rare but serious bone marrow failure disorder.
- Treatment strategies have evolved over time, impacting patient prognosis.
Purpose of the Study:
- To compare the long-term outcomes of pediatric aplastic anemia patients treated in two distinct eras.
- To evaluate the impact of changing treatment protocols on survival rates.
Main Methods:
- Retrospective comparison of two patient cohorts (1973-1988 vs. 1989-1996).
- Analysis of clinical history, age, aplasia severity, and treatment modalities.
- Actuarial survival rates assessed at eight years post-treatment.
Main Results:
- The recent cohort (1989-1996) demonstrated significantly better 8-year survival (84%) than the earlier cohort (1973-1988) (45%).
- Improved outcomes were observed for both immunosuppressive therapy (86% vs. 39%) and bone marrow transplantation (93% vs. 56%).
- No increased incidence of late clonal disorders or secondary malignancies was noted in survivors.
Conclusions:
- Prognosis for pediatric aplastic anemia has markedly improved due to advancements in treatment.
- Current therapeutic approaches offer over 80% long-term survival for affected children.
Abstract:
This study compared the prognosis of patients treated for aplastic anaemia at Great Ormond Street Hospital for Children from 1973-88 (group A; n = 38) with a more recent cohort from 1989-96 (group B; n = 37). The two groups were similar in terms of clinical history, age, and severity of aplasia. The main treatment differences included the use of androgen treatment in group A (21 of 38 patients) but not in group B, and the addition of cyclosporin A to immunosuppressive treatment for 14 patients in group B. Actuarial survival at eight years' follow up was significantly better for group B (84%; 95% CI, 68% to 93%) than for group A (45%; 95% CI, 30% to 60%), because of improved outcome for both immunosuppressive treatment (86% v 39%) and bone marrow transplantation (93% v 56%). There was no evidence for late clonal disorders or secondary malignancies in survivors in either group. The prognosis for aplastic anaemia has improved greatly in recent years so that over 80% of children are long term survivors.